References
- Tardy M, Huhn M, Engel RR, Leucht S. Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2014;10:CD009369.
- Seelig A, Gottschlich R, Devant RM. A method to determine the ability of drugs to diffuse through the blood–brain barrier . Proc Natl Acad Sci USA 1994;91:68–72.
- Mohamed S, Rosenheck RA, Lin HQ, et al. Randomized trial of the effect of four second-generation antipsychotics and one first-generation antipsychotic on cigarette smoking, alcohol, and drug use in chronic schizophrenia. J Nerv Ment Dis 2015;203:486–92.
- Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163:2080–9.
- Jin YY, Pollock BG, Coley K, et al. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol 2010;50:73–80.
- Hansen CE, Christensen TR, Elley J, et al. Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol 1976;3:915–23.
- Bruni G, Maietta M, Maggi L, et al. Perphenazine-fumaric acid salts with improved solubility: preparation, physico-chemical characterization and in vitro dissolution. Crystengcomm 2012;14:6035–44.
- Bruni G, Maggi L, Tammaro L, et al. Electrospun fibers as potential carrier systems for enhanced drug release of perphenazine. Int J Pharm 2016;511:190–7.
- Wang L, Xiao YY, Chen ML, et al. Pharmacokinetics of orally disintegrating tablets of perphenazine/hydroxypropyl-beta-cyclodextrin inclusion complex in rabbits. Pharmazie 2013;68:800–4.
- Wang L, Zeng F, Zong L. Development of orally disintegrating tablets of Perphenazine/hydroxypropyl-beta-cyclodextrin inclusion complex. Pharm Dev Technol 2013;18:1101–10.
- Turunen E, Mannila J, Laitinen R, et al. Fast-dissolving sublingual solid dispersion and cyclodextrin complex increase the absorption of perphenazine in rabbits. J Pharm Pharmacol 2011;63:19–25.
- Laitinen R, Suihko E, Bjorkqvist M, et al. Perphenazine solid dispersions for orally fast-disintegrating tablets: physical stability and formulation. Drug Dev Ind Pharm 2010;36:601–13.
- Turunen E, Korhonen O, Lehto VP, et al. Effect of storage on the dissolution rate of a fast-dissolving perphenazine/β-cyclodextrin complex. J Pharm Pharmacol 2014;66:367–77.
- Liu P, De Wulf O, Laru J, et al. Dissolution studies of poorly soluble drug nanosuspensions in non-sink conditions. AAPS PharmSciTech 2013;14:748–56.
- Cheow WS, Hadinoto K. Self-assembled amorphous drug–polyelectrolyte nanoparticle complex with enhanced dissolution rate and saturation solubility. J Colloid Interface Sci 2012;367:518–26.
- Cheow WS, Hadinoto K. Green preparation of antibiotic nanoparticle complex as potential anti-biofilm therapeutics via self-assembly amphiphile–polyelectrolyte complexation with dextran sulfate. Colloids Surf B: Biointerfaces 2012;92:55–63.
- Yousefpour P, Atyabi F, Farahani EV, et al. Polyanionic carbohydrate doxorubicin-dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations. Int J Nanomed 2011;6:1487–96.
- Cheow WS, Kiew TY, Yang Y, Hadinoto K. Amorphization strategy affects the stability and supersaturation profile of amorphous drug nanoparticles. Mol Pharm 2014;11:1611–20.
- Sun DD, Lee PI. Evolution of supersaturation of amorphous pharmaceuticals: the effect of rate of supersaturation generation. Mol Pharm 2013;10:4330–46.
- Patel A, Gaudana R, Mitra AK. A novel approach for antibody nanocarriers development through hydrophobic ion-pairing complexation. J Microencapsul 2014;31:542–50.
- Cook MT, Tzortzis G, Charalampopoulos D, Khutoryanskiy VV. Production and evaluation of dry alginate–chitosan microcapsules as an enteric delivery vehicle for probiotic bacteria. Biomacromolecules 2011;12:2834–40.
- Tiyaboonchai W, Limpeanchob N. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int J Pharm 2007;329:142–9.
- Halayqa M, Domanska U. PLGA biodegradable nanoparticles containing perphenazine or chlorpromazine hydrochloride: effect of formulation and release. Int J Mol Sci 2014;15:23909–23.
- Tajarobi F, Larsson A, Matic H, Abrahmsen-Alami S. The influence of crystallization inhibition of HPMC and HPMCAS on model substance dissolution and release in swellable matrix tablets. Eur J Pharm Biopharm 2011;78:125–33.